{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:17:31Z","timestamp":1761844651634},"reference-count":96,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.3892\/or.2016.5032","type":"journal-article","created":{"date-parts":[[2016,8,24]],"date-time":"2016-08-24T07:18:38Z","timestamp":1472023118000},"page":"1779-1786","source":"Crossref","is-referenced-by-count":16,"title":["Current treatments for advanced melanoma and introduction of a promising novel gene therapy for melanoma (Review)"],"prefix":"10.3892","volume":"36","author":[{"given":"Jae-Rim","family":"Heo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nam-Hyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaejin","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung-Chul","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2016,8,24]]},"reference":[{"key":"key20180107221213_b1-or-36-04-1779","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2174\/0929867323666151217122033","article-title":"Application of mesenchymal stem cells in melanoma: A potential therapeutic strategy for delivery of targeted agents","volume":"23","author":"Mirzaei","year":"2016","journal-title":"Curr Med Chem"},{"key":"key20180107221213_b2-or-36-04-1779","doi-asserted-by":"crossref","first-page":"516","DOI":"10.2340\/00015555-2035","article-title":"Metastatic melanoma - a review of current and future treatment options","volume":"95","author":"Maverakis","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"key20180107221213_b3-or-36-04-1779","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/CMR.0b013e3283632cbe","article-title":"Pulmonary metastasectomy for malignant melanoma: Prognostic factors for long-term survival","volume":"23","author":"Younes","year":"2013","journal-title":"Melanoma Res"},{"key":"key20180107221213_b4-or-36-04-1779","first-page":"389","article-title":"The role of surgery in the treatment of nonregionally recurrent melanoma","volume":"113","author":"Wong","year":"1993","journal-title":"Surgery"},{"key":"key20180107221213_b5-or-36-04-1779","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1002\/cncr.26111","article-title":"A phase 2 trial of complete resection for stage IV melanoma: Results of Southwest Oncology Group Clinical Trial S9430","volume":"117","author":"Sosman","year":"2011","journal-title":"Cancer"},{"key":"key20180107221213_b6-or-36-04-1779","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1200\/JCO.1984.2.2.131","article-title":"Vinblastine, bleomycin, and cis-platinum for the treatment of metastatic malignant melanoma","volume":"2","author":"National Cancer Institute of Canada Melanoma Group","year":"1984","journal-title":"J Clin Oncol"},{"key":"key20180107221213_b7-or-36-04-1779","first-page":"237","article-title":"Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma","volume":"11","author":"Kim","year":"2014","journal-title":"Cancer Biol Med"},{"key":"key20180107221213_b8-or-36-04-1779","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.ejca.2004.04.030","article-title":"Re-evaluating the role of dacarbazine in metastatic melanoma: What have we learned in 30 years?","volume":"40","author":"Eggermont","year":"2004","journal-title":"Eur J Cancer"},{"key":"key20180107221213_b9-or-36-04-1779","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00008390-200102000-00009","article-title":"Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: A meta-analysis of 3273 patients from 20 randomized trials","volume":"11","author":"Huncharek","year":"2001","journal-title":"Melanoma Res"},{"key":"key20180107221213_b10-or-36-04-1779","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","article-title":"Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma","volume":"18","author":"Middleton","year":"2000","journal-title":"J Clin Oncol"},{"key":"key20180107221213_b11-or-36-04-1779","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.1999.17.9.2745","article-title":"Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma","volume":"17","author":"Chapman","year":"1999","journal-title":"J Clin Oncol"},{"key":"key20180107221213_b12-or-36-04-1779","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1002\/1097-0142(19891115)64:10<2024::AID-CNCR2820641010>3.0.CO;2-V","article-title":"A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma","volume":"64","author":"Legha","year":"1989","journal-title":"Cancer"},{"key":"key20180107221213_b13-or-36-04-1779","doi-asserted-by":"crossref","first-page":"20","DOI":"10.12788\/jcso.0005","article-title":"Current options and future directions in the systemic treatment of metastatic melanoma","volume":"12","author":"A Schindler","year":"2014","journal-title":"J Community Support Oncol"},{"key":"key20180107221213_b14-or-36-04-1779","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"key20180107221213_b15-or-36-04-1779","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10637-009-9376-8","article-title":"A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-na\u00efve patients with advanced melanoma","volume":"29","author":"Hersh","year":"2011","journal-title":"Invest New Drugs"},{"key":"key20180107221213_b16-or-36-04-1779","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJMc1108661","article-title":"Ipilimumab plus dacarbazine in melanoma","volume":"365","author":"Kaplan","year":"2011","journal-title":"N Engl J Med"},{"key":"key20180107221213_b17-or-36-04-1779","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1002\/cncr.28282","article-title":"Clinical activity of ipilimumab for metastatic uveal melanoma: A retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience","volume":"119","author":"Luke","year":"2013","journal-title":"Cancer"},{"key":"key20180107221213_b18-or-36-04-1779","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J Clin Oncol"},{"key":"key20180107221213_b19-or-36-04-1779","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"key20180107221213_b20-or-36-04-1779","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nri2326","article-title":"Inhibitory B7-family molecules in the tumour microenvironment","volume":"8","author":"Zou","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"key20180107221213_b21-or-36-04-1779","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1084\/jem.20051776","article-title":"Tissue expression of PD-L1 mediates peripheral T cell tolerance","volume":"203","author":"Keir","year":"2006","journal-title":"J Exp Med"},{"key":"key20180107221213_b22-or-36-04-1779","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"key20180107221213_b23-or-36-04-1779","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med"},{"key":"key20180107221213_b24-or-36-04-1779","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"key20180107221213_b25-or-36-04-1779","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"key":"key20180107221213_b26-or-36-04-1779","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"key":"key20180107221213_b27-or-36-04-1779","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"key20180107221213_b28-or-36-04-1779","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"key20180107221213_b29-or-36-04-1779","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"key20180107221213_b30-or-36-04-1779","doi-asserted-by":"crossref","first-page":"7538","DOI":"10.1158\/1078-0432.CCR-09-1985","article-title":"Integrated molecular and clinical analysis of AKT activation in metastatic melanoma","volume":"15","author":"Davies","year":"2009","journal-title":"Clin Cancer Res"},{"key":"key20180107221213_b31-or-36-04-1779","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.critrevonc.2015.11.011","article-title":"Metastatic melanoma treatment: Combining old and new therapies","volume":"98","author":"Davey","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20180107221213_b32-or-36-04-1779","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N Engl J Med"},{"key":"key20180107221213_b33-or-36-04-1779","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nrclinonc.2011.69","article-title":"BRAF targeted therapy changes the treatment paradigm in melanoma","volume":"8","author":"Ribas","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"key20180107221213_b34-or-36-04-1779","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"key20180107221213_b35-or-36-04-1779","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nature09454","article-title":"Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma","volume":"467","author":"Bollag","year":"2010","journal-title":"Nature"},{"key":"key20180107221213_b36-or-36-04-1779","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N Engl J Med"},{"key":"key20180107221213_b37-or-36-04-1779","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","article-title":"Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): A multicentre, open-label, phase 2 trial","volume":"13","author":"Long","year":"2012","journal-title":"Lancet Oncol"},{"key":"key20180107221213_b38-or-36-04-1779","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1345\/aph.1Q363","article-title":"Vemurafenib (PLX4032): An orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma","volume":"45","author":"Heakal","year":"2011","journal-title":"Ann Pharmacother"},{"key":"key20180107221213_b39-or-36-04-1779","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1158\/1078-0432.CCR-11-2197","article-title":"Vemurafenib and BRAF inhibition: A new class of treatment for metastatic melanoma","volume":"18","author":"Luke","year":"2012","journal-title":"Clin Cancer Res"},{"key":"key20180107221213_b40-or-36-04-1779","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/978-1-62703-727-3_10","article-title":"Detecting mechanisms of acquired BRAF inhibitor resistance in melanoma","volume":"1102","author":"Lo","year":"2014","journal-title":"Methods Mol Biol"},{"key":"key20180107221213_b41-or-36-04-1779","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.ejca.2012.11.019","article-title":"Resistance to BRAF-targeted therapy in melanoma","volume":"49","author":"Sullivan","year":"2013","journal-title":"Eur J Cancer"},{"key":"key20180107221213_b42-or-36-04-1779","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nature10662","article-title":"RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)","volume":"480","author":"Poulikakos","year":"2011","journal-title":"Nature"},{"key":"key20180107221213_b43-or-36-04-1779","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-13-0642","article-title":"Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy","volume":"4","author":"Shi","year":"2014","journal-title":"Cancer Discov"},{"key":"key20180107221213_b44-or-36-04-1779","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ccr.2010.11.023","article-title":"Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R\/PI3K","volume":"18","author":"Villanueva","year":"2010","journal-title":"Cancer Cell"},{"key":"key20180107221213_b45-or-36-04-1779","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1755-148X.2010.00807.x","article-title":"The cadherin switch in melanoma instigated by HGF is mediated through epithelial-mesenchymal transition regulators","volume":"24","author":"Koefinger","year":"2011","journal-title":"Pigment Cell Melanoma Res"},{"key":"key20180107221213_b46-or-36-04-1779","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/CMR.0b013e328335a916","article-title":"Correlation of clinicopathological parameters with HGF, c-Met, EGFR, and IGF-1R expression in uveal melanoma","volume":"20","author":"Topcu-Yilmaz","year":"2010","journal-title":"Melanoma Res"},{"key":"key20180107221213_b47-or-36-04-1779","doi-asserted-by":"crossref","first-page":"2326s","DOI":"10.1158\/1078-0432.CCR-05-2517","article-title":"Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment","volume":"12","author":"Gajewski","year":"2006","journal-title":"Clin Cancer Res"},{"key":"key20180107221213_b48-or-36-04-1779","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1200\/JCO.2010.33.2312","article-title":"Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling","volume":"29","author":"Wagle","year":"2011","journal-title":"J Clin Oncol"},{"key":"key20180107221213_b49-or-36-04-1779","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1200\/JCO.2012.43.5966","article-title":"Phase II study of the MEK1\/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor","volume":"31","author":"Kim","year":"2013","journal-title":"J Clin Oncol"},{"key":"key20180107221213_b50-or-36-04-1779","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1158\/1078-0432.CCR-13-2054","article-title":"Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma","volume":"20","author":"Menzies","year":"2014","journal-title":"Clin Cancer Res"},{"key":"key20180107221213_b51-or-36-04-1779","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/j.1755-148X.2011.00891.x","article-title":"Embryonic stem-cell-preconditioned microenvironment induces loss of cancer cell properties in human melanoma cells","volume":"24","author":"Kim","year":"2011","journal-title":"Pigment Cell Melanoma Res"},{"key":"key20180107221213_b52-or-36-04-1779","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1158\/1078-0432.CCR-11-1491","article-title":"Phase II, open-label, randomized trial of the MEK1\/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma","volume":"18","author":"Kirkwood","year":"2012","journal-title":"Clin Cancer Res"},{"key":"key20180107221213_b53-or-36-04-1779","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"key20180107221213_b54-or-36-04-1779","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"key":"key20180107221213_b55-or-36-04-1779","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nrn1829","article-title":"Gene therapy: Can neural stem cells deliver?","volume":"7","author":"M\u00fcller","year":"2006","journal-title":"Nat Rev Neurosci"},{"key":"key20180107221213_b56-or-36-04-1779","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ymeth.2015.08.013","article-title":"Neural stem cell therapy for cancer","volume":"99","author":"Bago","year":"2016","journal-title":"Methods"},{"key":"key20180107221213_b57-or-36-04-1779","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1126\/science.287.5457.1433","article-title":"Mammalian neural stem cells","volume":"287","author":"Gage","year":"2000","journal-title":"Science"},{"key":"key20180107221213_b58-or-36-04-1779","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/74710","article-title":"Gene therapy of experimental brain tumors using neural progenitor cells","volume":"6","author":"Benedetti","year":"2000","journal-title":"Nat Med"},{"key":"key20180107221213_b59-or-36-04-1779","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1006\/mthe.2000.0046","article-title":"Neural precursor cells for delivery of replication-conditional HSV-1 vectors to intracerebral gliomas","volume":"1","author":"Herrlinger","year":"2000","journal-title":"Mol Ther"},{"key":"key20180107221213_b60-or-36-04-1779","doi-asserted-by":"crossref","first-page":"12846","DOI":"10.1073\/pnas.97.23.12846","article-title":"Neural stem cells display extensive tropism for pathology in adult brain: Evidence from intracranial gliomas","volume":"97","author":"Aboody","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180107221213_b61-or-36-04-1779","doi-asserted-by":"crossref","first-page":"14835","DOI":"10.1073\/pnas.0404180101","article-title":"Robust in vivo gene transfer into adult mammalian neural stem cells by lentiviral vectors","volume":"101","author":"Consiglio","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180107221213_b62-or-36-04-1779","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1158\/1541-7786.MCR-08-0146","article-title":"Neural stem cell tropism to glioma: Critical role of tumor hypoxia","volume":"6","author":"Zhao","year":"2008","journal-title":"Mol Cancer Res"},{"key":"key20180107221213_b63-or-36-04-1779","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1007\/s11064-012-0879-x","article-title":"The roles of hypoxia-inducible factors in regulating neural stem cells migration to glioma stem cells and determinating their fates","volume":"37","author":"Zhang","year":"2012","journal-title":"Neurochem Res"},{"key":"key20180107221213_b64-or-36-04-1779","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1172\/JCI200420001","article-title":"Neuronally expressed stem cell factor induces neural stem cell migration to areas of brain injury","volume":"113","author":"Sun","year":"2004","journal-title":"J Clin Invest"},{"key":"key20180107221213_b65-or-36-04-1779","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/jnr.21983","article-title":"Role of monocyte chemoattractant protein-1 (MCP-1\/CCL2) in migration of neural progenitor cells toward glial tumors","volume":"87","author":"Magge","year":"2009","journal-title":"J Neurosci Res"},{"key":"key20180107221213_b66-or-36-04-1779","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1021\/pr900020q","article-title":"Identification of gliotropic factors that induce human stem cell migration to malignant tumor","volume":"8","author":"An","year":"2009","journal-title":"J Proteome Res"},{"key":"key20180107221213_b67-or-36-04-1779","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1215\/S1152851704000754","article-title":"Neural stem cell migration toward gliomas in vitro","volume":"7","author":"Heese","year":"2005","journal-title":"Neuro Oncol"},{"key":"key20180107221213_b68-or-36-04-1779","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1593\/neo.04781","article-title":"Brain tumor tropism of transplanted human neural stem cells is induced by vascular endothelial growth factor","volume":"7","author":"Schmidt","year":"2005","journal-title":"Neoplasia"},{"key":"key20180107221213_b69-or-36-04-1779","doi-asserted-by":"crossref","first-page":"5550","DOI":"10.1158\/1078-0432.CCR-05-2508","article-title":"Human neural stem cells target experimental intracranial medulloblastoma and deliver a therapeutic gene leading to tumor regression","volume":"12","author":"Kim","year":"2006","journal-title":"Clin Cancer Res"},{"key":"key20180107221213_b70-or-36-04-1779","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/mt.2008.290","article-title":"Human neural stem cells can target and deliver therapeutic genes to breast cancer brain metastases","volume":"17","author":"Joo","year":"2009","journal-title":"Mol Ther"},{"key":"key20180107221213_b71-or-36-04-1779","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1371\/journal.pone.0000023","article-title":"Development of a tumor-selective approach to treat metastatic cancer","volume":"1","author":"Aboody","year":"2006","journal-title":"PLoS One"},{"key":"key20180107221213_b72-or-36-04-1779","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.1158\/0008-5472.CAN-07-0297","article-title":"Suicide gene therapy of human colon carcinoma xenografts using an armed oncolytic adenovirus expressing carboxypeptidase G2","volume":"67","author":"Schepelmann","year":"2007","journal-title":"Cancer Res"},{"key":"key20180107221213_b73-or-36-04-1779","doi-asserted-by":"crossref","first-page":"647","DOI":"10.2174\/156652306779010679","article-title":"Viral vectors for gene-directed enzyme prodrug therapy","volume":"6","author":"Schepelmann","year":"2006","journal-title":"Curr Gene Ther"},{"key":"key20180107221213_b74-or-36-04-1779","first-page":"1249","article-title":"Potential tumor-tropic effect of genetically engineered stem cells expressing suicide enzymes to selectively target invasive cancer in animal models","volume":"31","author":"Kim","year":"2011","journal-title":"Anticancer Res"},{"key":"key20180107221213_b75-or-36-04-1779","doi-asserted-by":"crossref","first-page":"5345","DOI":"10.1158\/0008-5472.CAN-06-4673","article-title":"Therapeutic efficacy of replication-competent retrovirus vector-mediated suicide gene therapy in a multifocal colorectal cancer metastasis model","volume":"67","author":"Hiraoka","year":"2007","journal-title":"Cancer Res"},{"key":"key20180107221213_b76-or-36-04-1779","first-page":"353","article-title":"Combine cancer gene therapy harnessing plasmids expressing human tumor necrosis factor alpha and Herpes simplex thymidine kinase suicide gene","volume":"53","author":"Pastorakova","year":"2006","journal-title":"Neoplasma"},{"key":"key20180107221213_b77-or-36-04-1779","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1089\/104303403322611782","article-title":"Intravascular delivery of neural stem cell lines to target intracranial and extracranial tumors of neural and non-neural origin","volume":"14","author":"Brown","year":"2003","journal-title":"Hum Gene Ther"},{"key":"key20180107221213_b78-or-36-04-1779","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/00130404-200305000-00007","article-title":"Neural stem cell biology may be well suited for improving brain tumor therapies","volume":"9","author":"Yip","year":"2003","journal-title":"Cancer J"},{"key":"key20180107221213_b79-or-36-04-1779","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1593\/neo.03427","article-title":"Glioma tropic neural stem cells consist of astrocytic precursors and their migratory capacity is mediated by CXCR4","volume":"6","author":"Ehtesham","year":"2004","journal-title":"Neoplasia"},{"key":"key20180107221213_b80-or-36-04-1779","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ccr.2006.03.003","article-title":"Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain","volume":"9","author":"Sun","year":"2006","journal-title":"Cancer Cell"},{"key":"key20180107221213_b81-or-36-04-1779","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/jnci\/djh004","article-title":"Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression","volume":"96","author":"Beppu","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"key20180107221213_b82-or-36-04-1779","doi-asserted-by":"crossref","first-page":"4747","DOI":"10.4049\/jimmunol.167.8.4747","article-title":"A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma","volume":"167","author":"Geminder","year":"2001","journal-title":"J Immunol"},{"key":"key20180107221213_b83-or-36-04-1779","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1634\/stemcells.2004-0342","article-title":"Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: Pivotal role of the SDF-1-CXCR4 axis","volume":"23","author":"Kucia","year":"2005","journal-title":"Stem Cells"},{"key":"key20180107221213_b84-or-36-04-1779","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1359-6101(01)00033-8","article-title":"Chemokines in cancer","volume":"13","author":"Vicari","year":"2002","journal-title":"Cytokine Growth Factor Rev"},{"key":"key20180107221213_b85-or-36-04-1779","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.molmed.2010.01.003","article-title":"Chemokines and chemokine receptors: New insights into cancer-related inflammation","volume":"16","author":"Lazennec","year":"2010","journal-title":"Trends Mol Med"},{"key":"key20180107221213_b86-or-36-04-1779","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1136\/thx.2009.128025","article-title":"Stem cells as vectors for antitumour therapy","volume":"65","author":"Loebinger","year":"2010","journal-title":"Thorax"},{"key":"key20180107221213_b87-or-36-04-1779","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/gt.2008.39","article-title":"Inflammation and tumor microenvironments: Defining the migratory itinerary of mesenchymal stem cells","volume":"15","author":"Spaeth","year":"2008","journal-title":"Gene Ther"},{"key":"key20180107221213_b88-or-36-04-1779","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/CAD.0000000000000046","article-title":"Targeted delivery of CYP2E1 recombinant adenovirus to malignant melanoma by bone marrow-derived mesenchymal stem cells as vehicles","volume":"25","author":"Wang","year":"2014","journal-title":"Anticancer Drugs"},{"key":"key20180107221213_b89-or-36-04-1779","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3892\/mmr.2016.5283","article-title":"Adipose derived mesenchymal stem cell facilitated TRAIL expression in melanoma treatment in vitro","volume":"14","author":"Jing","year":"2016","journal-title":"Mol Med Rep"},{"key":"key20180107221213_b90-or-36-04-1779","doi-asserted-by":"crossref","first-page":"944","DOI":"10.3109\/14653249.2011.584864","article-title":"Anti-tumor effects of canine adipose tissue-derived mesenchymal stromal cell-based interferon-\u03b2 gene therapy and cisplatin in a mouse melanoma model","volume":"13","author":"Seo","year":"2011","journal-title":"Cytotherapy"},{"key":"key20180107221213_b91-or-36-04-1779","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/jgm.2823","article-title":"Genetically engineered mesenchymal stromal cells producing TNF\u03b1 have tumour suppressing effect on human melanoma xenograft","volume":"17","author":"Tyciakova","year":"2015","journal-title":"J Gene Med"},{"key":"key20180107221213_b92-or-36-04-1779","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.scr.2013.09.010","article-title":"Selective antitumor effect of neural stem cells expressing cytosine deaminase and interferon-beta against ductal breast cancer cells in cellular and xenograft models","volume":"12","author":"Yi","year":"2014","journal-title":"Stem Cell Res (Amst)"},{"key":"key20180107221213_b93-or-36-04-1779","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3892\/ijo.2015.2999","article-title":"Additional effects of engineered stem cells expressing a therapeutic gene and interferon-\u03b2 in a xenograft mouse model of endometrial cancer","volume":"47","author":"Yi","year":"2015","journal-title":"Int J Oncol"},{"key":"key20180107221213_b94-or-36-04-1779","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.molonc.2013.01.004","article-title":"Suppression of the growth of human colorectal cancer cells by therapeutic stem cells expressing cytosine deaminase and interferon-\u03b2 via their tumor-tropic effect in cellular and xenograft mouse models","volume":"7","author":"Yi","year":"2013","journal-title":"Mol Oncol"},{"key":"key20180107221213_b95-or-36-04-1779","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.3892\/or.2013.2564","article-title":"Pancreatic tumor mass in a xenograft mouse model is decreased by treatment with therapeutic stem cells following introduction of therapeutic genes","volume":"30","author":"Kim","year":"2013","journal-title":"Oncol Rep"},{"key":"key20180107221213_b96-or-36-04-1779","doi-asserted-by":"crossref","first-page":"12835","DOI":"10.18632\/oncotarget.2547","article-title":"Co-treatment with therapeutic neural stem cells expressing carboxyl esterase and CPT-11 inhibit growth of primary and metastatic lung cancers in mice","volume":"5","author":"Yi","year":"2014","journal-title":"Oncotarget"}],"container-title":["Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/or.2016.5032\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T23:19:46Z","timestamp":1657149586000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/or.2016.5032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,24]]},"references-count":96,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,8,24]]},"published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.3892\/or.2016.5032"],"URL":"https:\/\/doi.org\/10.3892\/or.2016.5032","relation":{},"ISSN":["1021-335X","1791-2431"],"issn-type":[{"value":"1021-335X","type":"print"},{"value":"1791-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,24]]}}}